MedicinesPatentPool 375d ago

13 June 2025, Johannesburg – In parallel with the G20 Health Working Group, global health leaders are coming together in Johannesburg to set the foundation for a bold new phase of the mRNA Technology Transfer Programme – a pioneering initiative transitioning from proof of concept to sustainable, commercially viable manufacturing, while enhancing pandemic preparedness and regional health security. Launched in 2021 by the World Health Organization (WHO) and the Medicines Patent Pool (MPP), with the support of the Government of South Africa, France, Belgium, Canada, the European Union, Germany and Norway, the programme has successfully enabled 15 partners across Latin America, Africa, Eastern Europe and Asia to receive foundational mRNA technology. Now, it is moving into Phase 2.0 (2026–2030): Empowering regional manufacturers to scale up Good Manufacturing Practices (GMP) -grade, commercially sustainable production of mRNA-based vaccines and therapeutics. More: https://medicinespatentpool.org/news-publications-post/mrna-technology-transfer-programmes-phase-2-0-discussed-with-partners-on-the-sidelines-of-g20-summit To know more about the mRNA Technology Transfer Programme: www.mrnaProgramme.org and on LinkedIn: https://www.linkedin.com/company/mrna-technology-transfer-programme